Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs...
05 June 2021 - 6:15AM
Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company
employing its innovative asset-centric business model to discover,
develop and ultimately deliver impactful medicines to patients,
announced today that, in connection with its previously announced
initial public offering of 16,500,000 American Depositary Shares
(“ADSs”), the underwriters have fully exercised their option to
purchase an additional 2,475,000 ADSs at the initial public
offering price of $20.00 per ADS, less underwriting discounts and
commissions. The closing of the initial public offering occurred on
June 2, 2021 and the issuance and sale of the additional ADSs
closed today. The gross proceeds to Centessa from its initial
public offering, before deducting underwriting discounts,
commissions and other estimated offering expenses, totaled an
aggregate of $379.5 million.
Morgan Stanley, Goldman Sachs & Co. LLC, Jefferies, and
Evercore ISI acted as joint book-running managers for the
offering.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on May
27, 2021. The offering was made only by means of a written
prospectus. Copies of the final prospectus relating to the initial
public offering can be obtained, when available, from: Morgan
Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, New York 10014; Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street, New
York, NY 10282, by telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10012, by telephone at 877-821-7388 or by email at
prospectus_department@Jefferies.com; and Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, New York 10055, or by telephone at (888) 474 0200, or by
email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About CentessaCentessa Pharmaceuticals plc aims
to bring impactful new medicines to patients by combining the
strengths of an asset-centric model with the benefits of scale and
diversification typical of larger R&D organizations. The
asset-centric model refers to a highly specialized,
singular-focused company that is led by a team of well-recognized
subject matter experts. Centessa wholly owns ten of these
asset-centric companies. The companies’ programs range from
discovery-stage to late-stage development and include diverse
therapeutic areas including oncology, hematology,
immunology/inflammation, neuroscience, hepatology, pulmonology and
nephrology. Centessa’s asset-centric companies are overseen by the
Centessa management team, which sets overall strategy and
direction, provides leadership and expertise, and manages resource
allocation and shared infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements may be identified by words such as “aims,”
“anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will,” and variations of these words or
similar expressions that are intended to identify forward-looking
statements. Any such statements in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements.
Any forward-looking statements in this press release are based
on our current expectations, estimates and projections only as of
the date of this release and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, completion of the proposed public offering
on the anticipated terms, or at all, market conditions and the
satisfaction of customary closing conditions related to the initial
public offering. These and other risks concerning our programs and
operations are described in additional detail in its registration
statement on Form S-1, which is on file with the SEC. We explicitly
disclaim any obligation to update any forward-looking statements
except to the extent required by law.
Contacts:
Investor Contact: |
Media Contacts: |
Jennifer Porcelli, Head of
Investor Relations |
US |
Centessa Pharmaceuticals |
Dan Budwick, 1AB |
jennifer.porcelli@centessa.com |
dan@1abmedia.com |
|
|
|
UK/Greater
Europe |
|
Mary Clark & Shabnam Bashir,
Optimum Strategic Communications |
|
centessa@optimumcomms.com |
|
|
|
Switzerland |
|
Marcus Veith, VEITHing
Spirit |
|
marcus@vspirit.ch |
|
M: +41 79 20 75 111 |
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024